Research-Grade Peptides | 99%+ Purity Verified | US Delivery 2–5 Days
Save 5% with Crypto
SaiyanMed

Your Cart

No products in the cart.

Retatrutide vs. Tirzepatide: Triple vs. Dual Agonism

Retatrutide and tirzepatide represent different approaches to incretin-based metabolic research. While tirzepatide acts as a dual GIP/GLP-1 receptor agonist, retatrutide adds a third target — the glucagon receptor — creating a triple agonist profile.

GLP-1 Receptor Activation

Both compounds activate the GLP-1 receptor, which mediates glucose-dependent insulin secretion, delayed gastric emptying, and appetite regulation in preclinical models. The GLP-1 component is shared between the two molecules.

The Glucagon Component

Retatrutide’s additional glucagon receptor agonism is hypothesized to increase energy expenditure through thermogenesis and hepatic lipid oxidation. This third mechanism of action may enhance metabolic effects beyond what dual agonism provides.

Structural Differences

Tirzepatide is based on the GIP sequence with modifications for GLP-1 receptor binding. Retatrutide is built on a glucagon backbone with engineered GIP and GLP-1 receptor affinity. These structural choices determine receptor binding kinetics and pharmacokinetic profiles.